Loading cancer entity…
Loading cancer entity…
Clinical trials
805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05176665 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | unknown | Phase 1 / Phase 2 | 152 | Shanghai EpimAb Biotherapeutics Co., Ltd.INDUSTRY | 2 | Aug 26, 2024 | clinicaltrials |
| NCT05475210 | 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors | unknown | Phase 1 | 9 | Molecular Targeting Technologies, Inc.INDUSTRY | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04979611 | The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma | unknown | Phase 1 | 60 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03478358 | Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 60 | Peking Union Medical College HospitalOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03881306 | DEBOXA for Inoperable NET Liver Metastases | unknown | Phase 1 / Phase 2 | 60 | Xiangya Hospital of Central South UniversityOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT03629847 | Treatment of Neuroendocrine Tumors (NETs) With Combination of Everolimus and Radiolabeled Somatostatin Analogue | unknown | Phase 1 / Phase 2 | 30 | King Faisal Specialist Hospital & Research CenterOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03404414 | Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT | unknown | Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT03308682 | 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors | unknown | Phase 1 | 30 | Peking Union Medical College HospitalOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT01381822 | Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors(TH-CR-410) | unknown | Phase 1 | 58 | Threshold PharmaceuticalsINDUSTRY | 1 | Apr 21, 2014 | clinicaltrials |
| NCT02038738 | 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | unknown | Phase 1 / Phase 2 | 250 | Ochsner Health SystemOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT01175096 | Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor | unknown | Phase 1 / Phase 2 | 20 | Guangdong Provincial People's HospitalOTHER | 1 | Aug 4, 2010 | clinicaltrials |
| NCT00314925 | Safety Study of Seneca Valley Virus in Patients With Solid Tumors With Neuroendocrine Features | unknown | Phase 1 | 60 | NeotropixINDUSTRY | 1 | Feb 25, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Aug 26, 2024source: clinicaltrials